Ensifentrine,
does it really help with Improved week-12 FEV1 AUC0-12h, with symptoms, quality of life, and week-24 exacerbations assessed separately?
research showsThe grade is C. The prespecified shared primary endpoint, week-12 FEV1 AUC0-12h, improved by 87 mL and 94 mL versus placebo in both trials. Exacerbations were 24-week supportive outcomes, and symptoms and quality of life did not replicate in the second trial, giving C with 52 points.
ads claimImproved spirometry is real, but it does not establish equally large gains in daily breathlessness, quality of life, or hospitalization. Marketing should disclose that symptoms did not fully replicate and exacerbations were 24-week additional evidence.
Useful facts when choosing a product
- Ensifentrine is a nebulized prescription maintenance treatment that inhibits PDE3 and PDE4.
- ENHANCE-1 randomized 763 and analyzed 760; ENHANCE-2 randomized 790 and analyzed 789, so randomized and modified intention-to-treat denominators differ.
- No ensifentrine verdict appears in the existing 1,900-verdict ingredient list.
What the research actually shows
ENHANCE-1 randomized 763 and analyzed 760 treated participants, 477 versus 283, in modified intention-to-treat. ENHANCE-2 randomized 790 and analyzed 789, 498 versus 291. Both were double-blind phase 3 placebo-controlled trials with 12-week FEV1 AUC0-12h as the primary endpoint; 24-week symptoms and exacerbations were hierarchical or additional outcomes. Verona Pharma supported both trials and company employees were authors.
Why this is classified as C (52)
The manufacturer-only program replicated its lung-function primary endpoint, while symptoms and quality of life were inconsistent and exacerbations were supportive outcomes, giving C with 52 points.
Counterpoint. C does not deny the lung-function effect; it separates the confirmed primary effect from less-established patient-experienced and long-term exacerbation benefits.
Rejudgment record. Cross-check applied — The shared primary lung-function endpoint replicated within one manufacturer program, while symptoms and quality of life were inconsistent and exacerbations were 24-week supportive outcomes
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved week-12 FEV1 AUC0-12h | C | Two manufacturer replicate trials succeeded with +87 mL and +94 mL. |
| Improved symptoms and quality of life at week 24 | C | ENHANCE-1 was positive, but both E-RS and SGRQ failed in ENHANCE-2. |
| Reduced moderate or severe COPD exacerbations | C | Both trials favored treatment, but these were 24-week additional outcomes. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Multicenter double-blind randomized placebo-controlled phase 3 trial | 283 | Supported by manufacturer Verona Pharma | Primary endpoint: average FEV1 AUC0-12h at week 12 | +87 mL versus placebo (95% CI 55 to 119), P<0.001; week-24 E-RS -1.0 and SGRQ -2.3; exacerbation RR 0.64 (0.40 to 1.00), P=0.050. | Pivotal manufacturer-funded lung-function trial |
| Study 2 | Multicenter double-blind randomized placebo-controlled phase 3 trial | 291 | Supported by manufacturer Verona Pharma | Primary endpoint: average FEV1 AUC0-12h at week 12 | +94 mL versus placebo (95% CI 65 to 124), P<0.001; week-24 E-RS -0.6 (P=0.134), SGRQ -0.5 (P=0.669); exacerbation RR 0.57 (0.38 to 0.87), P=0.009. | Replicate trial within the same manufacturer program |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-08-01).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-01 · Corrections: none
Cite this verdict
[Chamgap] Ensifentrine x week-12 COPD lung-function improvement with mixed symptom and exacerbation results — Evidence Grade C·52. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/energy/ensifentrine-copd-lung-function-symptoms-exacerbations/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.